BioSpace News Archive

Deals

insitro Bolsters Machine-Learning Platform with Haystack Sciences Acquisition

Bay Area-based insitro snapped up neighboring Haystack Sciences to bolster its machine-learning drug discovery programs with that company’s higher resolution dataset-producing technology.

October 23, 2020
·
3 min read
·
Alex Keown
Business

Catalent Boosts Supply Chain Transparency in Response to COVID-19 Manufacturing Urgency

The pharmaceutical supply chain is being pushed to its limit as it prepares to deliver COVID-19 vaccines and therapeutics to the entire world as soon as possible, while continuing to produce and deliver all the usual medications and products.

October 23, 2020
·
4 min read
·
Gail Dutton
Drug Development

Study Suggests Bayer’s Finerenone Slows CKD Progression in Patients With Kidney Disease and T2D

The findings from Finerenone’s study were presented at the virtual American Society of Nephrology’s (ASN) Kidney Week 2020 on October 23, and the full study was published in a recent online edition of the New England Journal of Medicine.

October 23, 2020
·
3 min read
·
Brandon May
Policy

Former Indivior CEO Heading to Prison Over Role in Opioid Crisis

Shaun Thaxter, the former chief executive officer of Indivior, was sentenced in federal court Thursday, four months after pleading guilty to one misdemeanor count of sharing false information about the addictive properties of Suboxone Film, an opioid-based product.

October 23, 2020
·
2 min read
·
Alex Keown
FDA

Novartis Sees Glimmer of Hope for Branaplam in Huntington’s Disease

After discovering promising indicators on the path to the development of Branaplam (LMIO70) for spinal muscular atrophy, Novartis now hopes to repurpose the drug for the treatment of Hungtington’s disease.

October 23, 2020
·
2 min read
·
Heather McKenzie
Deals

Foghorn Booms onto Nasdaq with $120M IPO

Foghorn Therapeutics hits the Nasdaq offering 7.5 million shares at $16 apiece.

October 23, 2020
·
2 min read
·
Kate Goodwin
Deals

Could Arixa Pharmaceuticals’ Lead Product Pave the Way for More Efficient Antibiotics?

Arixa Pharmaceuticals announced on Thursday that Pfizer’s hospital business has agreed to acquire the company. Arixa has been developing oral antibiotics for antibiotic-resistant Gram-negative infections.

October 23, 2020
·
3 min read
·
Krystle Vermes
Policy

FDA COVID-19 Vaccine Advisory Committee: Lots of Talk, No Decisions, Some Reassurance

In the meeting, both the FDA and the U.S. Centers for Disease Control and Prevention presented details about COVID-19 and the requirements for a vaccine.

October 23, 2020
·
3 min read
·
Mark Terry
Deals

Retrophin Buys Orphan Technologies for $517 Million to Gain Enzyme Replacement Therapy

OT-58 is Orphan’s novel investigational enzyme replacement therapy. It is currently in Phase I/II development for classical HCU, a rare metabolic disorder marked by increased levels of plasma homocysteine.

October 23, 2020
·
3 min read
·
Mark Terry
Drug Development

FDA Greenlights Restart of AstraZeneca’s Phase III COVID-19 Vaccine Study

After nearly a month in limbo, AstraZeneca will resume Phase III testing of its COVID-19 vaccine candidate in the United States.

October 23, 2020
·
2 min read
·
Alex Keown